Polydex Pharmaceuticals (OTCMKTS:POLXF) Upgraded by ValuEngine to “Hold”

Polydex Pharmaceuticals (OTCMKTS:POLXF) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, ValuEngine reports.

OTCMKTS:POLXF opened at $0.99 on Wednesday. The firm has a market cap of $3.59 million, a P/E ratio of 9.55 and a beta of -0.27. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.84 and a current ratio of 4.16. Polydex Pharmaceuticals has a fifty-two week low of $0.75 and a fifty-two week high of $1.29. The firm has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.04.

Polydex Pharmaceuticals (OTCMKTS:POLXF) last released its quarterly earnings data on Monday, September 16th. The company reported $0.03 earnings per share for the quarter. The business had revenue of $1.24 million during the quarter. Polydex Pharmaceuticals had a net margin of 8.22% and a return on equity of 6.63%.

Polydex Pharmaceuticals Company Profile

Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry.

Featured Article: Earnings Per Share

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Polydex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polydex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.